Advances in MRI biomarkers for the diagnosis of Alzheimer's disease

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

StandardStandard

Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. / Kehoe, Elizabeth G; McNulty, Jonathan P; Mullins, Paul G et al.
Yn: Biomarkers in Medicine, Cyfrol 8, Rhif 9, 01.10.2014, t. 1151-69.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

HarvardHarvard

Kehoe, EG, McNulty, JP, Mullins, PG & Bokde, ALW 2014, 'Advances in MRI biomarkers for the diagnosis of Alzheimer's disease', Biomarkers in Medicine, cyfrol. 8, rhif 9, tt. 1151-69. https://doi.org/10.2217/bmm.14.42

APA

Kehoe, E. G., McNulty, J. P., Mullins, P. G., & Bokde, A. L. W. (2014). Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. Biomarkers in Medicine, 8(9), 1151-69. https://doi.org/10.2217/bmm.14.42

CBE

Kehoe EG, McNulty JP, Mullins PG, Bokde ALW. 2014. Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. Biomarkers in Medicine. 8(9):1151-69. https://doi.org/10.2217/bmm.14.42

MLA

Kehoe, Elizabeth G et al. "Advances in MRI biomarkers for the diagnosis of Alzheimer's disease". Biomarkers in Medicine. 2014, 8(9). 1151-69. https://doi.org/10.2217/bmm.14.42

VancouverVancouver

Kehoe EG, McNulty JP, Mullins PG, Bokde ALW. Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. Biomarkers in Medicine. 2014 Hyd 1;8(9):1151-69. doi: 10.2217/bmm.14.42

Author

Kehoe, Elizabeth G ; McNulty, Jonathan P ; Mullins, Paul G et al. / Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. Yn: Biomarkers in Medicine. 2014 ; Cyfrol 8, Rhif 9. tt. 1151-69.

RIS

TY - JOUR

T1 - Advances in MRI biomarkers for the diagnosis of Alzheimer's disease

AU - Kehoe, Elizabeth G

AU - McNulty, Jonathan P

AU - Mullins, Paul G

AU - Bokde, Arun L W

PY - 2014/10/1

Y1 - 2014/10/1

N2 - With the prevalence of Alzheimer's disease (AD) predicted to increase substantially over the coming decades, the development of effective biomarkers for the early detection of the disease is paramount. In this short review, the main neuroimaging techniques which have shown potential as biomarkers for AD are introduced, with a focus on MRI. Structural MRI measures of the hippocampus and medial temporal lobe are still the most clinically validated biomarkers for AD, but newer techniques such as functional MRI and diffusion tensor imaging offer great scope in tracking changes in the brain, particularly in functional and structural connectivity, which may precede gray matter atrophy. These new advances in neuroimaging methods require further development and crucially, standardization; however, before they are used as biomarkers to aid in the diagnosis of AD.

AB - With the prevalence of Alzheimer's disease (AD) predicted to increase substantially over the coming decades, the development of effective biomarkers for the early detection of the disease is paramount. In this short review, the main neuroimaging techniques which have shown potential as biomarkers for AD are introduced, with a focus on MRI. Structural MRI measures of the hippocampus and medial temporal lobe are still the most clinically validated biomarkers for AD, but newer techniques such as functional MRI and diffusion tensor imaging offer great scope in tracking changes in the brain, particularly in functional and structural connectivity, which may precede gray matter atrophy. These new advances in neuroimaging methods require further development and crucially, standardization; however, before they are used as biomarkers to aid in the diagnosis of AD.

KW - Alzheimer Disease

KW - Biomarkers

KW - Functional Neuroimaging

KW - Hippocampus

KW - Humans

KW - Magnetic Resonance Imaging

KW - Temporal Lobe

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.2217/bmm.14.42

DO - 10.2217/bmm.14.42

M3 - Article

C2 - 25402585

VL - 8

SP - 1151

EP - 1169

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 9

ER -